Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
News|Articles|September 2, 2004
- Pharmaceutical Technology-09-02-2004
- Volume 28
- Issue 9
Particulate-Free Pallets
Author(s)Hallie Forcinio
Particulate generation and durability concerns are encouraging pharmaceutical manufacturers to seek alternatives to wood pallets.
Advertisement
Articles in this issue
about 22 years ago
In the Spotlight-September 2004about 22 years ago
Promoting Quality in Drug Manufacturingabout 22 years ago
Automation in a Digital, Webbed, and Wireless Ageabout 22 years ago
September 2004about 22 years ago
Design of an Aseptic Process Simulationabout 22 years ago
Early Development Still Driving CRO PerformanceAdvertisement
Related to this article
USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
No operator touches a CAR-T batch before demonstrating proficiency. Generative AI users should meet the same standard, and a higher one, because an AI error does not stay inside one batch.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
2
Drapeau’s AI Deep Dive: Qualify the Reviewer Before the AI Goes Live
3
Meeting Tomorrow's Market Requirements: Vetter's Perspective on the Future of Fill & Finish
4
ADCs, Degraders, Agonists: 4 Deals CMC Teams Should Track
5